Overview

This trial is active, not recruiting.

Conditions constipation, chronic idiopathic constipation, cic
Treatment bli400 laxative
Phase phase 3
Sponsor Braintree Laboratories
Start date June 2016
End date March 2018
Trial size 330 participants
Trial identifier NCT02819310, BLI400-303

Summary

The objective of this study is to evaluate the safety of chronic use of BLI400 laxative in constipated adults.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
BLI400 Laxative
bli400 laxative
oral laxative

Primary Outcomes

Measure
% of subjects with treatment emergent adverse events
time frame: 12 months

Secondary Outcomes

Measure
Change in serum chemistry parameters
time frame: 12 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Male or female subjects at least 18 years of age 2. Constipated, defined by the following adapted ROME II definition: - Fewer than 3 spontaneous defecations per week and at least one of the following symptoms for at least 12 weeks (which need not be consecutive) in the preceding 12 months: - Straining during > 25% of defecations - Lumpy or hard stools in > 25% of defecations - Sensation of incomplete evacuation for > 25% of defecations 3. If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, sterilized, abstinent, or vasectomized spouse) 4. Negative urine pregnancy test at screening, if applicable 5. In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study Exclusion Criteria: 1. Report loose (mushy) or water stools in the absence of laxative use for more than 25% of BMs during the 12 weeks before Visit 1 2. Meet the Rome II criteria for Irritable Bowel Syndrome 3. Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon 4. Subjects who have had major surgery 30 days before Visit 1; appendectomy or cholecystectomy 60 days before Visit 1; abdominal, pelvic, or retroperitoneal surgery 6 months before Visit 1; bariatric surgery or surgery to remove a segment of the GI tract at any time before Visit 1 5. Subjects with hypothyroidism that is being treated and for which the dose of thyroid hormone has not been stable for at least 6 weeks at the time of Visit 1 6. Subjects taking laxatives, enemas or prokinetic agents that refuse to discontinue these treatments from Visit 1 until after completion of Visit 6 7. Subjects who are pregnant or lactating, or intend to become pregnant during the study 8. Subjects of childbearing potential who refuse a pregnancy test 9. Subjects who are allergic to any BLI400 component 10. Subjects taking narcotic analgesics or other medications known to cause constipation. 11. Subjects with clinically significant cardiac abnormalities identified at the Visit 1 ECG 12. Subjects with clinically significant laboratory abnormalities, deemed as a potential safety issue by the Investigator, may be discontinued at the Investigator's discretion. 13. Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures 14. Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days 15. Subjects with an active history of drug or alcohol abuse 16. Subjects have been hospitalized for a psychiatric condition or have made a suicide attempt during the 2 years before Visit 1 17. Subjects who withdraw consent at any time prior to completion of Visit 1 procedures

Additional Information

Official title An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Braintree Laboratories.